Publications by authors named "Avneet Heer"
Importance: In a randomized clinical trial, treatment guided by tumor-informed circulating tumor (ct)DNA testing reduced adjuvant chemotherapy use without compromising recurrence-free survival in patients with stage II colon cancer. The potential effects of adopting ctDNA testing into routine patient care is unknown.
Objective: To compare the total cost of patient care scenarios with and without the adoption of ctDNA testing.
Objective: Diagnosis of systemic lupus erythematosus (SLE) made by standard diagnostic laboratory tests (SDLTs) has sensitivity and specificity of 83% and 76%, respectively. A multivariate assay panel (MAP) combining complement C4d activation products on erythrocytes and B cells with SDLTs yields a sensitivity and specificity of 80% and 86%, respectively, presumably enabling earlier SLE diagnosis at lower severity, with associated lower health care costs compared with SDLT diagnoses. We compared the payer budget impact of diagnosing SLE using MAP (incremental cost of $108) versus SDLTs.
View Article and Find Full Text PDFArticle Synopsis
- Hundreds of patients with IL-12 or IL-23 deficiencies primarily experience invasive mycobacterial infections, due to impaired immune responses related to IFN-γ and IL-17A/IL-17F.
- A study found patients with complete deficiencies in IL-12Rβ2 or IL-23R who displayed mycobacteriosis without accompanying candidiasis, indicating a unique immune response profile.
- The research reveals that both IL-12 and IL-23 are crucial for the development of IFN-γ-producing CD4 T cells, and the lower incidence of symptoms in patients with IL-12Rβ2 or IL-23R deficiencies suggests these cytokines may partially compensate for each other’s absence.